Femasys announced the approval of an Investigational Device Exemption from the United States Food and Drug Administration to evaluate the safety and efficacy of FemBloc, a first-of-its-kind, non-surgical, non-implant, in-office solution for permanent birth control in a pivotal clinical trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FEMY:
- Femasys files to sell 3.39M shares of common stock for holders
- Femasys appoints Keith Kendall, Alistair Milnes to board of directors
- Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada
- Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting
- Femasys’ FemCerv receives product approval in Canada